Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2026)

Stoke Therapeutics has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 35.61% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (down 35.61% YoY), and the FY2025 full-year result was $7.0 million, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $6.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $49.5 million in Q1 2022, with the low at $6.6 million in Q1 2026.
• Average Non-Current Deffered Revenue over 5 years is $26.0 million, with a median of $29.1 million recorded in 2023.
• Year-over-year, Non-Current Deffered Revenue slumped 79.64% in 2024 and advanced 3.22% in 2025.
• Tracing STOK's Non-Current Deffered Revenue over 5 years: stood at $36.9 million in 2022, then dropped by 10.26% to $33.1 million in 2023, then plunged by 74.93% to $8.3 million in 2024, then dropped by 16.04% to $7.0 million in 2025, then slipped by 5.14% to $6.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $6.6 million (Q1 2026), $7.0 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.

Peer Comparison